1O' Connor P, Wolinsky J, Cofavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med, 2011, 365 : 1293-1303.
2Kappos L, Radue EW, O'Connor Pet al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med, 2010,362: 38%401.
3Kobashigawa J A, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med, 1995,333 : 621-627.
4McCarey DW, Mclnnes IB, Madhoek R, et al. Trial of atorvastatin in rheumatoid arthritis ( TARA ): double-blind, randomised placebo-controlled trial. Lancet, 2004, 363:2015-2021.
5Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, et al . Therapy with statins in patients with refractory rheumatic diseases: a.preliminary study. Lupus, 2003, 12 : 607-611.
6Stanisiaus R, Singh A K, Singh I. Lovastatin treatment decreases mononuclear cell infiltrationinto the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res, 2001, 66: 155-162.
7Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420: 78-84.
8Viglietta V, Baecher-A]lan C, Weiner HL, et al. Loss of functional suppression by CD4 + CD25 + regulatory T cells in patients with multiple sclerosis. J Exp Med, 2004,199:971-979.
9Huan J, Culbertson N, Spencer L, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res, 2005,81:45-52.
10Venken K, Hellings N, Hensen K, et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4 + CD25 + regulatory T-cell function and FOXP3 expression. J Neurosci Res, 2006,83 : 1432-1446.
